Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-intensified temozolomide rechallenge in recurrent glioblastoma
ISRCTN68738654Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Sep 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Median time to treatment failure. Started Sep 2009; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ISRCTN68738654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68738654.